Follow Up on a Congress Poster With Evidence Maturity in View

A department chair stops you after a session and says the poster you both saw looks promising. That question sounds simple, but it puts you in a tight spot. A poster is an early snapshot, not a finished body of evidence, and the person asking wants a straight answer about what it means for their patients today. How you handle the next two minutes says a lot about your credibility as a scientific resource.

Why this conversation goes wrong

MSLs get into trouble here in one of two ways. Some liaisons treat the poster as if it already carries the weight of a full publication, walking a clinician through conclusions the data cannot yet support. Others get so cautious that they refuse to engage with the actual findings, and the clinician walks away feeling like the conversation was a dodge. Neither response respects what a poster actually is. A poster typically reports interim results, a small cohort, a single arm, or preliminary safety signals before peer review has tested the methods and statistics. The abstract review process for most congresses is far lighter than journal peer review. Sample sizes are often small, follow up periods short, and the analysis plan sometimes finalized after the data came in. None of that makes the poster worthless. It means the honest answer to should we change anything is almost always not yet, and your job is to explain why in a way that keeps the clinician engaged rather than shut down.

How to prepare before you respond

Before you say anything definitive, find out exactly what the clinician saw. A person who read the full poster at the session has a different starting point than someone who only caught a summary slide or a secondhand mention on social media. Ask directly which one applies. Then pull up the poster yourself and read the stated objective, the methods, the results, and the limitations section line by line. Note the sample size, the study design, whether it was randomized or observational, whether the primary endpoint was met, and what the authors themselves flagged as unresolved. Check whether a full manuscript is in preparation or already submitted, since that changes what you can promise about timing. If the poster touches on an endpoint that clinicians tend to misread, revisit how you frame endpoint data before you walk in. The post on how to Discuss Study Endpoints Without Overreading Them covers that ground well and pairs naturally with this scenario. Have two or three related published papers ready to mention, even if only by topic, so you have something concrete to offer beyond the poster itself.

What to say when the clinician asks

Keep your opening response focused on process, not conclusions. When the chair says, "The poster looked promising. Should our group change anything?" you answer, "I can walk you through exactly what the poster reports and where the authors say the evidence still needs to develop. Which part matters most to you right now?"

The chair comes back with, "My main concern is the sample size. It looked small for the claims being made." You respond directly. "You are right to flag that. The poster enrolled a small number of patients in a single arm, and the authors list that as a limitation themselves. That is exactly the kind of gap a poster leaves open before a larger trial reports."

The chair then asks, "Is anything more definitive coming?" You say, "A fuller analysis or manuscript is not available yet. I can send you two published studies that address this same question in a larger sample, and I will flag you as soon as anything further from this program becomes public." That gives the chair a real next step instead of a flat no, and it keeps the door open for another conversation once the evidence moves forward.

Mistakes that undercut your credibility

The most common mistake is filling the silence with reassurance you cannot back up. If a clinician senses hesitation and you respond with something like, it does look like a strong signal, you have handed them a conclusion the data does not support, and that phrase will get repeated back to you later. Another mistake is treating every question as a request for medical advice and shutting the conversation down entirely. Refusing to discuss the poster's actual content because it feels like unapproved territory ignores the difference between describing a source and recommending a practice change. You can do the first without ever touching the second. A third mistake is guessing at details you have not verified. If you do not remember the exact confidence interval or the exact number of patients enrolled, say you will confirm it and follow up, rather than approximating in the moment. A wrong number from an MSL travels fast and costs trust that takes years to rebuild. Finally, avoid promising a timeline for publication or additional data that you do not control. Say what you know, say what you do not know, and say what you will check.

How to practice and score this exchange

A manager coaching an MSL on this scenario should build the drill around three checkpoints rather than a single pass or fail grade. First, did the liaison confirm what the clinician actually saw before answering. Second, did the liaison stick to what the poster reports and its stated limitations without adding interpretation the authors did not offer. Third, did the liaison close with a concrete next step, whether that is a related publication, a manuscript timeline, or a scheduled follow up once more data exists. Score each rehearsal on those three points and keep a short note of the source discussed, the clinician's specific question, and the evidence route offered next. Over time that log shows whether a liaison tends to overclaim, underengage, or land in the middle where they should be. Rehearsing this with an AI counterpart before congress season lets a liaison hear how a rushed answer sounds out loud, which is usually the first sign it needs work. DealSpeak's Pharmaceuticals practice conversations include this exact scenario alongside other formats an MSL runs into during and after a congress, and running through it a few times before the meetings start builds the kind of fluency that only shows up under real pressure. If your clinicians tend to push toward guideline questions once the poster discussion ends, the post on how to Support a Guideline Evidence Request With Neutral Sources picks up where this one leaves off.

A poster is a starting point, not a verdict, and most clinicians know that even when their questions sound like they want a final answer. Answer what the data actually shows, name what remains open, and give them a real path to more evidence. That combination builds more trust over a career than any single confident sounding answer ever will.